HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Apelin, diabetes, and obesity.

Abstract : Apelin is a peptide known as the ligand of the G-protein-coupled receptor APJ. Several active apelin forms exist such as apelin-36, apelin-17, apelin-13, and the pyroglutamated form of apelin-13. Apelin and APJ are expressed in the central nervous system, particularly in the hypothalamus and in many peripheral tissues. Apelin has been shown to be involved in the regulation of cardiovascular and fluid homeostasis, food intake, cell proliferation, and angiogenesis. In addition to be an ubiquitous peptide, apelin is also produced and secreted by adipocytes and thus considered as an adipokine. This has opened a new field of investigation establishing a link between apelin and metabolic disorders (obesity, type 2 diabetes, etc.) which is the focus of the present review. Several studies, but not all, have reported an increase of plasma apelin concentrations in humans and in animal models with different metabolic pathologies. Moreover, important roles for apelin both in glucose and lipid metabolism have been highlighted as well as the associated signaling pathways. Apelin appears as a beneficial adipokine with anti-obesity and anti-diabetic properties and thus as a promising therapeutic target in metabolic disorders.
Document type :
Journal articles
Complete list of metadata

Contributor : Marie Francoise Simon Connect in order to contact the contributor
Submitted on : Tuesday, August 30, 2011 - 9:08:34 AM
Last modification on : Wednesday, January 12, 2022 - 2:24:03 PM

Links full text




Isabelle Castan-Laurell, Cédric Dray, Camille Attané, Thibaut Duparc, Claude Knauf, et al.. Apelin, diabetes, and obesity.. Endocrine, Springer, 2011, 40 (1), pp.1-9. ⟨10.1007/s12020-011-9507-9⟩. ⟨inserm-00617638⟩



Record views